Hubei Jumpcan Pharmaceutical Co., Ltd.

600566.SS

600566.SSHubei Jumpcan Pharmaceutical Co., Ltd. CN flag

Shanghai Stock Exchange

26.00

CNY

+0.13

(+0.50%)

2.32EPS

11.21P/E

23.83BMarket Cap

Aug 18Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE0000018X6

Return %

Stock

S&P500

-20.10

12.30

2.36

62.46

-4.52

98.55

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	3.15	4.01	3.85	4.83	5.86	6.96	8.88	8.51	7.39	8.61	10.11	10.53	8.74	7.78
Basic EPS, GAAP	0.39	0.66	0.67	0.88	1.17	1.51	2.08	1.99	1.53	1.94	2.44	3.08	2.76	2.32
Free Cash Flow per Basic Share	-0.01	0.03	0.41	0.32	0.74	0.55	1.28	1.96	1.62	1.86	2.67	3.45	2.18	-0.12
Dividend per Share	0.54	0.03	0.05	0.4	0.69	0.73	1	1.23	1.21	0.46	0.68	0.9	1.33	1.32
Book Value per Share	1.04	1.2	1.57	1.95	2.4	3.15	4.26	5	5.25	6.44	8.19	10.15	11.6	12.07
Tangible Book Value per Share	1.18	1.67	2.78	2.99	4.13	4.95	6.15	6.87	8.76	9.8	12.21	14.06	15.53	16.02
Basic Weighted Avg Shares	609	610	775	780	798	810	811	816	835	886	890	916	917	917
Sales/Revenue/Turnover	1,920	2,448	2,986	3,768	4,678	5,642	7,208	6,940	6,165	7,631	8,996	9,655	8,017	7,140
Operating Margin (%)	13.05	17.73	18.74	19.93	22.48	24.28	26.23	26.13	22.73	22.15	25.68	30.05	30.18	29.34
Depreciation Expense	47	61	81	109	117	152	176	232	281	294	309	303	308	- -
Net Income, GAAP	238	403	519	687	934	1,223	1,688	1,623	1,277	1,719	2,171	2,823	2,532	2,127
Effective Tax Rate (%)	17.2	13.37	14.1	14.56	14.12	14.74	14.62	14.27	13.91	11.96	13.41	14.26	14.83	14.86
Profit Margin (%)	12.38	16.45	17.39	18.22	19.97	21.68	23.42	23.39	20.72	22.53	24.13	29.24	31.58	29.79
Working Capital	-95	115	943	878	1,527	2,222	2,691	3,072	4,607	5,322	7,749	9,644	11,164	11,670
LT Debt	110	- -	- -	- -	- -	698	553	576	605	1	- -	1	1	1
Total Equity	750	1,152	2,294	2,713	3,688	4,402	5,480	6,104	7,763	9,131	11,352	13,369	14,726	15,167
Return on Invested Capital (%)	21.39	29.59	24.08	24.23	28.11	26.44	28.94	24.43	15.98	16.38	18.47	18.82	13.62	11.17
Return on Capital (%)	33.02	42.1	42.05	45.25	53.18	47.22	47.32	38.09	27.07	30.89	31.25	31.36	23.37	18.2
Return on Common Equity (%)	54.35	59	53.35	50.23	54.35	54.72	56.2	43.11	30.19	34.07	33.41	34.03	25.4	20.04

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	11.58%	4.17%	-16.96%
Net Income, GAAP	19.26%	11.86%	-10.32%
Free Cash Flow	32.67%	9.39%	-36.69%
Total Cash Common Dividend	85.96%	14.54%	47.92%
Total Equity	20.65%	19.41%	10.15%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Fei Cao
Full Time Employees: 5,230
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: Baota Bay Taixing People's Republic of China 225441
IPO Date: Aug 22, 2001
Website: jumpcan.com
Similar Companies: CanSino Biologics Inc. (6185.HK)
Radient Technologies Inc. (RTI.V)
Suheung Co., Ltd. (008490.KS)
LIWANLI Innovation Co., Ltd. (3054.TW)
Canntab Therapeutics Limited (PILL.CN)
KYORIN Holdings, Inc. (4569.T)
Business: Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. The company offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatrics; oral and skin care products; and anti-fatigue, anti-aging, antioxidant, and immunity-enhancing Chinese medicine health products. It also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis. The company was formerly known as Hubei Hongcheng General Machinery Co., Ltd and changed its name to Hubei Jumpcan Pharmaceutical Co., Ltd. in March 2015. Hubei Jumpcan Pharmaceutical Co., Ltd. is based in Taixing, China.

	Sep'24	Dec'24	Mar'25
Total Current Assets	14,350	14,702	14,637
Accounts Receivable, Net	1,869	2,173	1,393
Cash, Cash Equivalents & STI	11,701	11,830	12,583
Inventories	664	569	457
Total Current Liabilities	3,854	3,538	2,967
Payables & Accruals	- -	- -	- -
ST Debt	1,181	788	628
Deferred Revenue	- -	- -	- -

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	3.15	4.01	3.85	4.83	5.86	6.96	8.88	8.51	7.39	8.61	10.11	10.53	8.74	7.78
Basic EPS, GAAP	0.39	0.66	0.67	0.88	1.17	1.51	2.08	1.99	1.53	1.94	2.44	3.08	2.76	2.32
Free Cash Flow per Basic Share	-0.01	0.03	0.41	0.32	0.74	0.55	1.28	1.96	1.62	1.86	2.67	3.45	2.18	-0.12
Dividend per Share	0.54	0.03	0.05	0.4	0.69	0.73	1	1.23	1.21	0.46	0.68	0.9	1.33	1.32
Book Value per Share	1.04	1.2	1.57	1.95	2.4	3.15	4.26	5	5.25	6.44	8.19	10.15	11.6	12.07
Tangible Book Value per Share	1.18	1.67	2.78	2.99	4.13	4.95	6.15	6.87	8.76	9.8	12.21	14.06	15.53	16.02
Basic Weighted Avg Shares	609	610	775	780	798	810	811	816	835	886	890	916	917	917
Sales/Revenue/Turnover	1,920	2,448	2,986	3,768	4,678	5,642	7,208	6,940	6,165	7,631	8,996	9,655	8,017	7,140
Operating Margin (%)	13.05	17.73	18.74	19.93	22.48	24.28	26.23	26.13	22.73	22.15	25.68	30.05	30.18	29.34
Depreciation Expense	47	61	81	109	117	152	176	232	281	294	309	303	308	- -
Net Income, GAAP	238	403	519	687	934	1,223	1,688	1,623	1,277	1,719	2,171	2,823	2,532	2,127
Effective Tax Rate (%)	17.2	13.37	14.1	14.56	14.12	14.74	14.62	14.27	13.91	11.96	13.41	14.26	14.83	14.86
Profit Margin (%)	12.38	16.45	17.39	18.22	19.97	21.68	23.42	23.39	20.72	22.53	24.13	29.24	31.58	29.79
Working Capital	-95	115	943	878	1,527	2,222	2,691	3,072	4,607	5,322	7,749	9,644	11,164	11,670
LT Debt	110	- -	- -	- -	- -	698	553	576	605	1	- -	1	1	1
Total Equity	750	1,152	2,294	2,713	3,688	4,402	5,480	6,104	7,763	9,131	11,352	13,369	14,726	15,167
Return on Invested Capital (%)	21.39	29.59	24.08	24.23	28.11	26.44	28.94	24.43	15.98	16.38	18.47	18.82	13.62	11.17
Return on Capital (%)	33.02	42.1	42.05	45.25	53.18	47.22	47.32	38.09	27.07	30.89	31.25	31.36	23.37	18.2
Return on Common Equity (%)	54.35	59	53.35	50.23	54.35	54.72	56.2	43.11	30.19	34.07	33.41	34.03	25.4	20.04

Year	Q1	Q2	Q3	Q4	FY
2023	2,388	2,241	1,908	3,118	9,655
2024	2,403	1,632	1,771	2,212	8,017
2025	1,525	- -	- -	- -	- -

	Sep'24	Dec'24	Mar'25
ST Debt	1,181	788	628
LT Borrowings	- -	- -	- -
LT Finance Leases	1	1	1
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	922	922	922
Market Capitalization	28,776	26,718	25,503

Hubei Jumpcan Pharmaceutical Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year